natgillin/translations-raw huggingface dataset:
No specific interaction studies with Ovitrelle and other medicinal products have been performed however no clinically significant medicinal product interactions have been reported during hCG therapy.
Nisu provedena specifična ispitivanja interakcija lijeka Ovitrelle s drugim lijekovima, a tijekom terapije hCG-om nisu zabilježene klinički značajne interakcije s lijekovima.
No specific interaction studies with Ovitrelle and other medicinal products have been performed, however no clinically significant medicinal product interactions have been reported during hCG therapy.
Nisu provedena specifična ispitivanja interakcija lijeka Ovitrelle s drugim lijekovima, a tijekom terapije hCG-om nisu zabilježene klinički značajne interakcije s lijekovima.
No specific paediatric group has been studied at present.
Trenutno nema ispitivanja u posebnim pedijatrijskim skupinama.
No specific pharmacokinetic studies have been performed in patients with hepatic or renal insufficiency, or in elderly people.
Nisu provedena posebna farmakokinetička ispitivanja u bolesnika s insuficijencijom jetre ili bubrega ili u starijih osoba.
No specific risk factors were identified in those subjects who experienced a TEE with the exception of platelet counts ≥ 200,000/µl (see section 4.4).
Nisu identificirani specifični čimbenici rizika u ispitanika koji su doživjeli tromboembolijski događaj s iznimkom broja trombocita ≥ 200 000/µl (vidjeti dio 4.4).
No specific side effects have been reported when Enurev Breezhaler has been taken together with other products used to treat COPD such as reliever inhalers (e.g. salbutamol), methylxanthines (e.g. theophylline) and/or oral and inhaled steroids (e.g. prednisolone).
Nisu prijavljene posebne nuspojave kada se Enurev Breezhaler primjenjivao istodobno s drugim lijekovima koji se primjenjuju za liječenje KOPB-a kao što su inhalatori za olakšavanje tegoba (npr. salbutamol), metilksantini (npr. teofilin) i/ili oralni i inhalacijski steroidi (npr. prednizolon).
No specific side effects have been reported when Seebri Breezhaler has been taken together with other products used to treat COPD such as reliever inhalers (e.g. salbutamol), methylxanthines (e.g. theophylline) and/or oral and inhaled steroids (e.g. prednisolone).
Nisu prijavljene posebne nuspojave kada se Seebri Breezhaler primjenjivao istodobno s drugim lijekovima koji se primjenjuju za liječenje KOPB-a kao što su inhalatori za olakšavanje tegoba (npr. salbutamol), metilksantini (npr. teofilin) i/ili oralni i inhalacijski steroidi (npr. prednizolon).
No specific side effects have been reported when Tovanor Breezhaler has been taken together with other products used to treat COPD such as reliever inhalers (e.g. salbutamol), methylxanthines (e.g. theophylline) and/or oral and inhaled steroids (e.g. prednisolone).
Nisu prijavljene posebne nuspojave kada se Tovanor Breezhaler primjenjivao istodobno s drugim lijekovima koji se primjenjuju za liječenje KOPB-a kao što su inhalatori za olakšavanje tegoba (npr. salbutamol), metilksantini (npr. teofilin) i/ili oralni i inhalacijski steroidi (npr. prednizolon).
No specific studies have been conducted to assess the effect of ketoconazole on the ability to drive or use machines.
Nisu provedena posebna ispitivanja o utjecaju ketokonazola na sposobnost upravljanja vozilima i rada sa strojevima.
No specific studies have been conducted to demonstrate absence of interferences from maternally derived antibodies on vaccine take.
Nisu provedena specifična istraživanja koja bi dokazala izostanak utjecaja antitijela, prenesenih s majke na primjenu vakcine.
No specific studies have been performed to evaluate the effects of gender, age, race, and body weight on ponatinib pharmacokinetics.
Nisu provedena ispitivanja za ocjenu utjecaja spola, dobi, rase i tjelesne težine na farmakokinetiku ponatiniba.
No specific studies in animals have been performed to evaluate the effect of obinutuzumab on fertility.
Nisu provedena posebna istraživanja na životinjama kojima bi se ocijenio utjecaj obinutuzumaba na plodnost.
No specific studies with aflibercept have been conducted in animals to evaluate the effect on fertility.
Nisu provedena posebna istraživanja na životinjama kojima bi se ocijenio učinak aflibercepta na plodnost.
No specific studies with Benlysta have been conducted in patients with hepatic impairment.
Nisu provedene specifične studije s lijekom Benlysta u bolesnika s oštećenjem jetre.
No specific studies with rivaroxaban in humans have been conducted to evaluate effects on fertility.
Specifična ispitivanja s rivaroksabanom u ljudi radi procjene učinka na plodnost nisu provedena.
No specific studies with vemurafenib have been conducted in animals to evaluate the effect on fertility.
Nisu provedena posebna ispitivanja na životinjama kako bi se procijenio učinak vemurafeniba na plodnost.
No specific study on fertility has been conducted.
Nisu provedena posebna ispitivanja utjecaja na plodnost.
No spontaneous post-marketing reports of MRI interference have been received to date.
Nakon stavljanja lijeka u promet, do danas nisu zaprimljene spontane prijave smetnji kod MRI-ja.
No staining is observed or membrane staining is observed in < 10 % of the tumour cells
Nema vidljive obojenosti ili se obojenost membrane primjećuje u < 10 % tumorskih stanica.
No starting dose adjustment for Kyprolis is required in patients with baseline mild, moderate, or severe renal impairment or patients on chronic dialysis.
Nije potrebna prilagodba početne doze za Kyprolis u bolesnika koji na početku terapije imaju blago, umjereno ili teško oštećenje bubrega ili u bolesnika na kroničnoj dijalizi.
No statistical comparisons to placebo were made at week 24 in studies 2 and 4 because the original placebo group began receiving Enbrel 25 mg BIW or 50 mg once weekly from week 13 to week 24.
Nisu rađene statističke usporedbe s placebom u 24. tjednu u ispitivanjima 2 i 4 budući da je izvorna placebo skupina počela primati Enbrel 25 mg dva puta tjedno ili 50 mg jednom tjedno od 13. do 24. tjedna.
No statistically significant benefit of early routine eptifibatide strategy was demonstrated in the subgroup of patients who were managed medically or during the medical management periods prior to PCI or CABG.
Statistički se značajna dobrobit rane rutinske primjene eptifibatida nije pokazala u podskupini bolesnika koji su ne-kirurški liječeni ili tijekom liječenja u koronarnoj jedinici prije PCI ili CABG.
No statistically significant benefit of early routine eptifibatide strategy was demonstrated in the subgroup of patients who were managed medically or during the medical management periods prior to PCI or CABG.
Statistički se značajna dobrobit rane rutinske primjene eptifibatida nije pokazala u podskupini bolesnika koji su ne-kirurški liječeni ili tijekom nekirurškog liječenja prije PCI ili CABG.
No statistically significant benefit of early routine eptifibatide strategy was demonstrated in the subgroup of patients who were managed medically or during the medical management periods prior to PCI or CABG.
Statistički se značajna dobrobit rane rutinske primjene eptifibatida nije pokazala u podskupini bolesnika koji su nekirurški liječeni ili tijekom liječenja u koronarnoj jedinici prije PCI ili CABG.
No statistically significant difference in the incidence of the primary composite endpoint (cardiovascular death, non-fatal myocardial infarction, non-fatal stroke, or hospitalization for congestive heart failure) was found [15.7 % in the telmisartan and 17.0 % in the placebo groups with a hazard ratio of 0.92 (95 % CI 0.81 - 1.05, p = 0.22)].
Nije pronađena statistički značajna razlika u incidenciji primarnog kompozitnog ishoda (kardiovaskularna smrt, nefatalni infarkt miokarda, nefatalni moždani udar ili hospitalizacija zbog kongestivnog zatajenja srca) [15,7 % u skupini na telmisartanu i 17,0 % u skupini na placebu, s omjerom rizika od 0,92 (95 % CI 0,81 – 1,05, p = 0,22)].
No statistically significant difference in the incidence of the primary composite endpoint (cardiovascular death, non-fatal myocardial infarction, non-fatal stroke, or hospitalization for congestive heart failure) was found [15.7 % in the telmisartan and 17.0 % in the placebo groups with a hazard ratio of 0.92 (95 % CI 0.81 - 1.05, p = 0.22)].
Nije pronađena statistički značajna razlika u incidenciji primarnog kompozitnog ishoda (kardiovaskularna smrt, nefatalni infarkt miokarda, nefatalni moždani udar ili hospitalizacija zbog kongestivnog zatajenja srca) [15,7 % u skupini na telmisartanu i 17,0 % u skupini na placebu, s omjerom rizika od 0,92 (95 % CI 0,81 – 1.05, p = 0,22)].
No statistically significant difference in the incidence of the primary composite endpoint (cardiovascular death, non-fatal myocardial infarction, non-fatal stroke, or hospitalization for congestive heart failure) was found [15.7 % in the telmisartan and 17.0 % in the placebo groups with a hazard ratio of 0.92 (95 % CI 0.81 - 1.05, p = 0.22)].
Nije pronađena statistički značajna razlika u incidenciji primarnog kompozitnog ishoda (kardiovaskularna smrt, nefatalni infarkt miokarda, nefatalni moždani udar ili hospitalizacija zbog kongestivnog zatajenja srca) [15,7% u skupini na telmisartanu i 17,0% u skupini na placebu, s omjerom rizika od 0,92 (95% CI 0,81 – 1,05, p = 0,22)].
No statistically significant difference in the incidence of the primary composite endpoint (cardiovascular death, non-fatal myocardial infarction, non-fatal stroke, or hospitalization for congestive heart failure) was found [15.7 % in the telmisartan and 17.0 % in the placebo groups with a hazard ratio of 0.92 (95 % CI 0.81 - 1.05, p = 0.22)].
Nije pronađena statistički značajna razlika u incidenciji primarnog složenog ishoda (kardiovaskularna smrt, nefatalni infarkt miokarda, nefatalni moždani udar ili hospitalizacija zbog kongestivnog zatajenja srca) [15,7 % u skupini na telmisartanu i 17,0 % u skupini na placebu s omjerom hazarda od 0,92 (95 % CI 0,81 – 1,05, p = 0,22)].
No statistically significant difference in the incidence of the primary composite endpoint (cardiovascular death, non-fatal myocardial infarction, non-fatal stroke, or hospitalization for congestive heart failure) was found [15.7 % in the telmisartan and 17.0 % in the placebo groups with a hazard ratio of 0.92 (95 % CI 0.81 - 1.05, p = 0.22)].
Nije pronađena statistički značajna razlika u incidenciji primarnog složenog ishoda (kardiovaskularna smrt, nefatalni infarkt miokarda, nefatalni moždani udar ili hospitalizacija zbog kongestivnog zatajenja srca) [15,7 % u skupini na telmisartanu i 17,0 % u skupini na placebu s omjerom rizika od 0,92 (95 % CI 0,81 – 1,05, p = 0,22)].
No statistically significant difference in the incidence of the primary composite endpoint (cardiovascular death, non-fatal myocardial infarction, non-fatal stroke, or hospitalization for congestive heart failure) was found [15.7 % in the telmisartan and 17.0 % in the placebo groups with a hazard ratio of 0.92 (95 % CI 0.81 - 1.05, p = 0.22)].
Nije pronađena statistički značajna razlika u učestalosti primarnog složenog ishoda (kardiovaskularna smrt, nefatalni infarkt miokarda, nefatalni moždani udar ili hospitalizacija zbog kongestivnog zatajenja srca) [15,7 % u skupini na telmisartanu i 17,0 % u skupini na placebu s omjerom rizika od 0,92 (95 % CI 0,81 – 1,05, p = 0,22)].
No statistically significant difference in the incidence of the primary composite endpoint (cardiovascular death, non-fatal myocardial infarction, non-fatal stroke, or hospitalization for congestive heart failure) was found [15.7% in the telmisartan and 17.0% in the placebo groups with a hazard ratio of 0.92 (95% CI 0.81-1.05, p = 0.22)].
Nije pronađena statistički značajna razlika u incidenciji primarnog složenog ishoda (kardiovaskularna smrt, nefatalni infarkt miokarda, nefatalni moždani udar ili hospitalizacija zbog kongestivnog zatajenja srca) [15,7% u skupini na telmisartanu i 17,0% u skupini na placebu s omjerom hazarda od 0,92 (95% CI 0,81 – 1,05, p = 0,22)].
No statistically significant differences in any other individual Grade 3 / 4 / 5 adverse reactions were seen with longer exposure.
Nisu uočene statistički značajne razlike između skupina za bilo koju drugu pojedinačnu nuspojavu stupnjeva 3/4/5 pri duljoj izloženosti lijeku.
No statistically significant differences in any other individual Grade 3/4/5 adverse reactions were seen with longer exposure.
Uočene su i statistički značajne razlike u nalazima testova plućne funkcije.
No statistically significant differences in the overall incidence of bleeding events were observed between Nplate and placebo treated patients.
Statistički nema značajne razlike u ukupnoj incidenciji događaja krvarenja između bolesnika liječenih Nplateom ili placebom.
No studies have been conducted in children with renal impairment.
Nisu provođene studije kod djece s bubrežnim oštećenjem.
No studies have been conducted in paediatric patients.
Nisu provedena ispitivanja kod pedijatrijskih bolesnica.
No studies have been conducted in women older than 26 years of age.
Nisu provedena ispitivanja u žena starijih od 26 godina.
No studies have been conducted to assess the impact of mirabegron on milk production in humans, its presence in human breast milk, or its effects on the breast-fed child.
Nisu provedena ispitivanja radi procjene utjecaja mirabegrona na stvaranje majčinog mlijeka kod ljudi, njegove prisutnosti u majčinom mlijeku ili njegovu učinku na dojenu djecu.
No studies have been conducted to evaluate carcinogenicity or mutagenicity of aflibercept.
Nisu provedena ispitivanja kojima bi se ocijenila kancerogenost ili mutagenost aflibercepta.
No studies have been conducted to investigate the pharmacokinetics of dabrafenib in paediatric patients.
Nije provedeno niti jedno ispitivanje farmakokinetike dabrafeniba u pedijatrijskih bolesnika.
No studies have been conducted to investigate the pharmacokinetics of olaparib in paediatric patients.
Nisu provedena ispitivanja kojima bi se ocijenila farmakokinetika olapariba u pedijatrijskih bolesnica.
No studies have been conducted to investigate the pharmacokinetics of riociguat in paediatric patients.
Nisu provedena ispitivanja farmakokinetike riocigvata u pedijatrijskoj populaciji.
No studies have been conducted to investigate the pharmacokinetics of vemurafenib in paediatric patients.
Nisu provedena ispitivanja farmakokinetike vemurafeniba u pedijatrijskih bolesnika.
No studies have been conducted with conversion of patients from Advagraf to Envarsus; however, data from healthy volunteers would suggest that the same conversion rate is applicable as with the conversion from Prograf to Envarsus.
Ispitivanja nisu bila provedena s prelaskom bolesnika sa Adagrafa na Envarsus, međutim podaci dobiveni kod zdravih dobrovoljaca ukazuju da se može primijeniti ista brzina prelaska kao i kod prelaska s Prografa na Envarsus.
No studies have been conducted with DuoTrav or with timolol 5 mg/ml eye drops in patients with hepatic or renal impairment.
Nisu provedene studije s DuoTrav kapima niti s timololom 5 mg/ml kapima za oko u bolesnika s oštećenjem jetre ili bubrega.
No studies have been conducted with Translarna in patients with renal or hepatic impairment.
Nisu provedena ispitivanja s lijekom Translarna u bolesnika s oštećenjem funkcije bubrega ili jetre.
No studies have been conducted.
Nisu provedena ispitivanja.
No studies have been performed in patients with hepatic impairment and therefore Inovelon should not be administered to patients with severe hepatic impairment(see section 4.2).
Nisu provedena ispitivanja u bolesnika s oštećenjem funkcije jetre pa se stoga Inovelon ne smije primjenjivati u bolesnika s teškim oštećenjem funkcije jetre (vidjeti dio 4.2).
No studies have been performed in patients with hepatic impairment.
Nisu provedena ispitivanja kod bolesnika s oštećenom funkcijom jetre.
No studies have been performed in patients with impaired renal function and use in such patients is not recommended (see section 4.4).
Nisu provedena ispitivanja u pacijenata s oštećenjem funkcije bubrega te se ne preporučuje uporaba u takvih pacijenata (vidjeti dio 4.4).
No studies have been performed in sick or convalescent cats, therefore this veterinary medicinal product should only be used based on the benefit-risk assessment of the responsible veterinarian.
Nisu provedena ispitivanja na bolesnim ili mačkama koje se oporavljaju te bi se stoga ovaj veterinarsko-medicinski proizvod trebao koristiti samo na temelju procjene koristi i rizika odgovornog veterinara.
No studies have been performed in the paediatric population (see section 4.2).
Na pedijatrijskoj populaciji nisu provedena ispitivanja (vidjeti dio 4.2).
No studies have been performed to investigate the pharmacokinetics of SANCUSO in paediatrics.
Nisu provedena ispitivanja farmakokinetike lijeka SANCUSO u pedijatrijskih bolesnika.
No studies have been performed with Xultophy in children and adolescents below 18 years of age.
Nisu provedena ispitivanja s lijekom Xultophy u djece i adolescenata mlađih od 18 godina.
No studies in pregnant women have been conducted.
Nisu provedena ispitivanja u trudnica.
No studies investigating the effect of pegaspargase on fertility have been performed.
Nisu provedena ispitivanja utjecaja pegaspargaze na plodnost.
No studies of Certifect in the treatment of lice were presented, as field studies previously presented for the medicine containing fipronil and (S)- methoprene were considered sufficient.
Nisu dostavljena ispitivanja djelotvornosti VMP-a Certifect u liječenju uši, s obzirom da su prethodno dostavljena terenska ispitivanja za VMP koji sadrži fipronil i (S)-metopren smatrana dostatnima.
No studies of interaction with other medicinal products have been performed.
Nisu provedena ispitivanja interakcija s drugim lijekovima.
No studies of reproductive toxicity were conducted with pegaspargase.
Nisu provedena ispitivanja reproduktivne toksičnosti s pegaspargazom.
No studies of the effects of Emselex on the ability to drive and use machines have been performed.
Ispitivanja učinaka Emselexa na sposobnost upravljanja motornim vozilima i strojevima nisu provedena.
No studies of the effects on the ability to drive and use machines have been performed.
Nisu provedena ispitivanja o utjecaju na sposobnost upravljanja vozilima i rada sa strojevima.
No studies of the effects on the ability to drive and use machines have been performed.
Nisu provedene studije o učincima na sposobnost upravljanja vozilima i rada na strojevima.
No studies of the effects on the ability to drive and use machines have been performed.
Nisu provedene studije utjecaja na sposobnost upravljanja vozilima i rada sa strojevima.
No studies on fertility have been performed.
Nisu provedena ispitivanja plodnosti.
No studies on fertility have been performed.
Nisu provedena istraživanja plodnosti.
No studies on pharmacokinetic and pharmacodynamics interaction between Repatha and lipid-lowering drugs other than statins and ezetimibe have been conducted.
Osim za statine i ezetimib, nisu provedena druga ispitivanja farmakokinetičkih i farmakodinamičkih interakcija između lijeka Repatha i lijekova za snižavanje lipida.
No studies on the ability to drive and use machines have been conducted.
Nisu provedena ispitivanja učinka na sposobnost upravljanja vozilima i rada sa strojevima.
No studies on the effect on human fertility have been conducted for Jentadueto.
Nisu provedena ispitivanja učinka Jentadueta na ljudsku plodnost.
No studies on the effect on the ability to drive and use machines have been performed.
Nisu provedena ispitivanja utjecaja na sposobnost upravljanja vozilima i rada sa strojevima.
No studies on the effect on the ability to drive and use machines have been performed.
Nisu provedene nikakve studije o učincima na sposobnost upravljanja vozilima i rada sa strojevima.
No studies on the effects of Arzerra on the ability to drive and use machines have been performed.
Nisu provođena ispitivanja o učincima lijeka Arzerra na sposobnost upravljanja vozilima i rada sa strojevima.
No studies on the effects of AVONEX on the ability to drive and use machines have been performed.
Nisu provedena ispitivanja o učincima AVONEXA na sposobnost upravljanja vozilima i rada sa strojevima.
No studies on the effects of cobicistat on the ability to drive and use machines have been performed.
Nisu provedena ispitivanja učinaka kobicistata na sposobnost upravljanja vozilima i rada sa strojevima.
No studies on the effects of elvitegravir on the ability to drive and use machines have been performed.
Nisu provedena ispitivanja utjecaja elvitegravira na sposobnost upravljanja vozilima i rada sa strojevima.
No studies on the effects of LEMTRADA on the ability to drive and use machines have been performed.
Nisu provedena ispitivanja utjecaja lijeka LEMTRADA na sposobnost upravljanja vozilima i rada sa strojevima.
No studies on the effects of MabThera on the ability to drive and use machines have been performed, although the pharmacological activity and adverse reactions reported to date suggest that MabThera would have no or negligible influence on the ability to drive and use machines.
Nisu provedena ispitivanja o utjecaju lijeka MabThera na sposobnost upravljanja vozilima i rada sa strojevima, iako farmakološka aktivnost i dosad prijavljene nuspojave ukazuju na to da MabThera ne utječe ili zanemarivo utječe na sposobnost upravljanja vozilima i rada sa strojevima.
No studies on the effects of tacrolimus (Envarsus) on the ability to drive and use machines have been performed.
Nisu provedena ispitivanja utjecaja takrolimusa (Envarsus) na sposobnost upravljanja vozilima i rada sa strojevima.
No studies on the effects of the ability to drive and use machines have been performed.
Nisu provedena ispitivanja utjecaja na sposobnost upravljanja vozilima i rada sa strojevima.
No studies on the effects on ability to drive and use machines have been performed.
Nisu provedena ispitivanja o učincima abakavira i lamivudina na sposobnost upravljanja vozilima i rada sa strojevima.
No studies on the effects on the ability to drive and use machines have been performed with IOA.
Nisu provedena ispitivanja učinaka lijeka IOA na sposobnost upravljanja vozilima i rada sa strojevima.
No studies on the effects on the ability to drive and use machines have been performed.
Ispitivanja utjecaja na sposobnost upravljanja vozilima i rada sa strojevima nisu se provodila.
No studies on the effects on the ability to drive and use machines have been performed.
Nema studija o utjecaju na sposobnost upravljanja vozilima i rada sa strojevima.
No studies on the effects on the ability to drive and use machines have been performed.
Nije bilo obavljenih studija učinaka na sposobnost vožnje i upravljanja strojevima
No studies on the effects on the ability to drive and use machines have been performed.
Nisu provedena ispitivanja na učinke na sposobnost upravljanja vozilima i rada sa strojevima.
No studies on the effects on the ability to drive and use machines have been performed.
Nisu provedena ispitivanja o utjecaju ovoga lijeka na sposobnost upravljanja motornim vozilima i sposobnost rukovanja strojevima.
No studies on the effects on the ability to drive and use machines have been performed.
Nisu provedena ispitivanja učinaka lijeka Aprovel na sposobnost upravljanja vozilima i strojevima.
No studies on the effects on the ability to drive and use machines have been performed.
Nisu provedena ispitivanja učinaka lijeka Irbesartan Zentiva na sposobnost upravljanja vozilima i strojevima.
No studies on the effects on the ability to drive and use machines have been performed.
Nisu provedena ispitivanja učinaka lijeka Karvea na sposobnost upravljanja vozilima i strojevima.
No studies on the effects on the ability to drive and use machines have been performed.
Nisu provedena ispitivanja učinaka lijeka na sposobnost upravljanja vozilima i strojevima.
No studies on the effects on the ability to drive and use machines have been performed.
Nisu provedena ispitivanja učinka lijeka na sposobnost upravljanja vozilima i rada na strojevima.
No studies on the effects on the ability to drive and use machines have been performed.
Nisu provedena ispitivanja učinka na sposobnost upravljanja vozilima i rada sa strojevima.